Clinical Trial Phases

Early Stopping Rules in Phase 1 Trials: Safety, PK, and Futility Criteria

Posted on digi By digi

Phase 1 clinical trials are designed to explore safety, pharmacokinetics (PK), and tolerability of a new investigational drug. Given the first-in-human exposure and potential unknown risks, early stopping rules are essential safeguards built into the trial protocol. These rules provide clear, predefined criteria that guide investigators, sponsors, and safety committees in deciding whether a study should be paused or permanently terminated. This tutorial explores different types of early stopping rules—based on safety, PK data, and futility—and provides examples and best practices for implementing them in a compliant and operationally sound manner.
Click to read the full article.

Phase 1 (Safety and Dosage)

Labeling Negotiations and Risk Communication After Phase 3 Trials: Process, Stakeholders, and Best Practices

Posted on digi By digi

After a Phase 3 trial concludes and a regulatory submission is underway, a crucial next step is product labeling. The label—also called the prescribing information or product monograph—defines how the drug will be used by physicians and patients. It must reflect the clinical evidence, especially from Phase 3 trials, and communicate benefits, risks, and appropriate usage clearly and accurately.
Click to read the full article.

Phase 3 (Confirmation and Monitoring)

Recruitment and Retention Strategies in Phase 2

Posted on digi By digi

Phase 2 clinical trials are critical for evaluating a drug’s efficacy, refining dosage, and identifying early safety signals. Yet, one of the most common reasons for delays and failures in Phase 2 is poor patient recruitment and retention. With increasing protocol complexity, growing competition, and diverse eligibility requirements, trial teams must adopt well-planned, data-driven, and patient-centric strategies to recruit and retain participants. This tutorial outlines proven methods, practical tools, and regulatory-aligned tactics to enhance recruitment and retention in Phase 2 studies.
Click to read the full article.

Phase 2 (Efficacy and Side Effects)

Economic Outcomes and Cost-Effectiveness in Phase 4 Clinical Trials

Posted on digi By digi

Once a drug enters the market, its clinical benefit must translate into real-world value—not only in health outcomes but also in terms of cost and resource use. That’s where Phase 4 clinical trials play a key role in generating economic evidence. These post-marketing studies are crucial for evaluating how a therapy performs in the context of healthcare systems, payer policies, and patient affordability.
Click to read the full article.

Phase 4 (Post-Marketing Surveillance)

Phase 1 Studies for Biosimilars: PK, PD, and Immunogenicity Assessment

Posted on digi By digi

Biosimilars—biologic products that are highly similar to an approved reference product—must undergo rigorous evaluation to demonstrate similarity in structure, function, and clinical performance. Phase 1 clinical trials are a cornerstone of biosimilar development and focus primarily on pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity. These studies are not designed to establish efficacy per se but to confirm that the biosimilar behaves similarly to the originator biologic in healthy subjects or patients. This tutorial explains the strategic design and regulatory expectations for Phase 1 biosimilar trials.
Click to read the full article.

Phase 1 (Safety and Dosage)

Sample Size Calculation for Phase 2 Trials

Posted on digi By digi

Determining the appropriate sample size in a Phase 2 clinical trial is a critical step that directly affects the trial’s ability to detect meaningful treatment effects, avoid underpowered results, and prevent unnecessary exposure of patients to experimental drugs. Unlike Phase 1 (focused on safety) or Phase 3 (powered for confirmatory efficacy), Phase 2 trials strike a delicate balance between exploration and decision-making. This tutorial covers the principles, methods, and practical steps involved in calculating sample size for Phase 2 studies.
Click to read the full article.

Phase 2 (Efficacy and Side Effects)

Adherence and Compliance Studies in Phase 4 Clinical Trials: Real-World Challenges and Strategies

Posted on digi By digi

Clinical trial results often assume optimal patient behavior. However, in the real world, the true impact of a drug depends on whether patients take it consistently and correctly. Non-adherence can lead to treatment failure, higher healthcare costs, and safety risks. That’s why Phase 4 clinical trials play a crucial role in evaluating medication adherence and developing strategies to improve compliance and persistence.
Click to read the full article.

Phase 4 (Post-Marketing Surveillance)

Placebo Control in Phase 1: When and Why It’s Used

Posted on digi By digi

In Phase 1 clinical trials—especially first-in-human studies—the primary goal is to evaluate the safety, tolerability, pharmacokinetics (PK), and sometimes pharmacodynamics (PD) of an investigational drug. While efficacy is not the main objective at this stage, placebo control is often incorporated to support data integrity, enable unbiased safety interpretation, and comply with regulatory guidance. This tutorial delves into the rationale for using placebo arms in Phase 1, when they are most appropriate, how they are structured, and the ethical and operational considerations involved.
Click to read the full article.

Phase 1 (Safety and Dosage)

Bayesian Approaches in Phase 2 Designs

Posted on digi By digi

Phase 2 clinical trials are a critical stage for evaluating preliminary efficacy, determining optimal dosing, and making go/no-go decisions. Increasingly, sponsors are turning to Bayesian statistical methods in Phase 2 designs to increase flexibility, incorporate prior knowledge, and optimize decision-making under uncertainty. Bayesian designs can be especially advantageous in early-phase trials where traditional fixed-sample frequentist approaches may lack efficiency or adaptability. This tutorial explains the fundamentals of Bayesian approaches in Phase 2, their applications, and regulatory considerations.
Click to read the full article.

Phase 2 (Efficacy and Side Effects)